Best Clean Energy Stocks To Own For 2019

If you’re looking to invest in renewable power stocks, you can always pick out pure plays that take advantage of the huge demand for clean energy —  and with utility customers inking long-term power contracts as they switch from dirty carbon-based fuels, that might be a winning strategy. However, what if the growth story behind renewables doesn’t live up to today’s hype?

That uncertainty is why a diversified company like NextEra Energy, Inc. (NYSE:NEE), with utility and renewable power operations, might make more sense for conservative investors.

Focusing on renewables

There’s no question that a company like Brookfield Renewable Partners L.P. (NYSE:BEP) is a great direct play on renewable power. Roughly 80% of the company’s power is hydroelectric, with the rest made up largely of wind and solar. Moreover, it has exposure to Brazil (20% of generation) and Columbia (15%), in addition to the United States (60%). Much of the company’s growth has come from acquisitions, and long-term contracts back up the bulk of its revenues. It’s a perfectly fine renewable power investment.

Best Clean Energy Stocks To Own For 2019: John B. Sanfilippo & Son, Inc.(JBSS)

Advisors’ Opinion:

  • [By Max Byerly]

    John B. Sanfilippo & Son, Inc. (NASDAQ:JBSS) shares reached a new 52-week high and low during trading on Wednesday . The stock traded as low as $71.43 and last traded at $70.96, with a volume of 1305 shares trading hands. The stock had previously closed at $69.72.

  • [By Max Byerly]

    The Hershey (NYSE: HSY) and John B. Sanfilippo & Son (NASDAQ:JBSS) are both consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

  • [By Stephan Byrd]

    WINTON GROUP Ltd acquired a new position in shares of John B. Sanfilippo & Son, Inc. (NASDAQ:JBSS) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 21,466 shares of the company’s stock, valued at approximately $1,242,000. WINTON GROUP Ltd owned about 0.19% of John B. Sanfilippo & Son at the end of the most recent quarter.

  • [By Ethan Ryder]

    John B. Sanfilippo & Son, Inc. (NASDAQ:JBSS) CEO Jeffrey T. Sanfilippo sold 8,108 shares of the firm’s stock in a transaction that occurred on Thursday, August 30th. The shares were sold at an average price of $71.00, for a total transaction of $575,668.00. Following the completion of the sale, the chief executive officer now directly owns 14,840 shares in the company, valued at approximately $1,053,640. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Best Clean Energy Stocks To Own For 2019: TrueBlue Inc.(TBI)

Advisors’ Opinion:

  • [By Logan Wallace]

    Trueblue (NYSE: TBI) is one of 23 public companies in the “Help supply services” industry, but how does it contrast to its rivals? We will compare Trueblue to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, earnings and risk.

  • [By Stephan Byrd]

    American Century Companies Inc. grew its holdings in shares of Trueblue Inc (NYSE:TBI) by 24.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 95,307 shares of the business services provider’s stock after purchasing an additional 18,680 shares during the period. American Century Companies Inc. owned approximately 0.23% of Trueblue worth $2,468,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    Russell Investments Group Ltd. grew its stake in Trueblue Inc (NYSE:TBI) by 21.2% during the first quarter, HoldingsChannel reports. The fund owned 137,178 shares of the business services provider’s stock after purchasing an additional 23,951 shares during the quarter. Russell Investments Group Ltd.’s holdings in Trueblue were worth $3,553,000 at the end of the most recent quarter.

  • [By Motley Fool Transcribers]

    TrueBlue Inc  (NYSE:TBI)Q4 2018 Earnings Conference CallFeb. 07, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    Trueblue Inc (NYSE:TBI) has received a consensus rating of “Hold” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $27.50.

  • [By Logan Wallace]

    Media stories about Trueblue (NYSE:TBI) have trended somewhat positive on Monday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Trueblue earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the business services provider an impact score of 45.3296498009881 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Best Clean Energy Stocks To Own For 2019: Adaptimmune Therapeutics plc(ADAP)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Adaptimmune Therapeutics (NASDAQ:ADAP) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.20, Bloomberg Earnings reports. Adaptimmune Therapeutics had a negative return on equity of 32.26% and a negative net margin of 185.39%. During the same quarter in the prior year, the business earned ($3.00) EPS.

  • [By Stephan Byrd]

    Adaptimmune Therapeutics (NASDAQ:ADAP) was downgraded by stock analysts at TheStreet from a “c-” rating to a “d+” rating in a research report issued to clients and investors on Monday.

  • [By Logan Wallace]

    Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

  • [By ]

    Adaptimmune Therapeutics (ADAP) : “If you’ve speculated on this one, you’ve won. Let’s move on.”

    Icahn Enterprises (IEP) : “I don’t really know what they own so I can’t recommend it.”

  • [By Logan Wallace]

    Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

    Get Adaptimmune Therapeutics alerts:

    Analysts Anticipate Adaptimmune Therapeutics PLC – (ADAP) to Post -$0.28 Earnings Per Share (americanbankingnews.com) Peritoneal Cancer Market Pipeline Review H1- Target Drug Profile, Top Industry Intelligence, Major Key Players and … (thefreenewsman.com) Escherichia coli Infections Market Research Report Pipeline Review H1 Assessment by Mechanism of Action, Drug … (theperfectinvestor.com) Adaptimmune Therapeutics plc (ADAP): Do You Have This Stock in Portfolio?: (bitcoinpriceupdate.review)

    Several equities analysts have weighed in on the company. Leerink Swann reissued an “outperform” rating on shares of Adaptimmune Therapeutics in a report on Thursday, March 15th. BidaskClub downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. ValuEngine upgraded Adaptimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday. SunTrust Banks increased their target price on Adaptimmune Therapeutics to $18.00 and gave the stock a “buy” rating in a research report on Thursday, May 10th. Finally, Cowen restated a “buy” rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, May 9th. Two equities research analysts have rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $16.94.

  • [By ]

    Cramer was bearish on Chesapeake Energy (CHK) , Adaptimmune Therapeutics (ADAP) , Icahn Enterprises (IEP) , Bristol-Myers Squibb (BMY) , Quad/Graphics (QUAD) , Spectra Energy Partners (SEP) and L Brands (LB) .

Best Clean Energy Stocks To Own For 2019: SPDR S&P Bank ETF (KBE)

Advisors’ Opinion:

  • [By Jim Crumly]

    Several big banks reported earnings, but their shares slumped today; the SPDR S&P Bank ETF (NYSEMKT:KBE) fell 1.1%. Consumer stocks had a good showing, with the Consumer Staples Select Sector SPDR ETF (NYSEMKT:XLP) up 0.7%.

  • [By Max Byerly]

    Key Square Capital Management LLC bought a new position in shares of SPDR KBW Bank (NYSEARCA:KBE) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 403,000 shares of the exchange traded fund’s stock, valued at approximately $19,300,000. SPDR KBW Bank comprises 2.2% of Key Square Capital Management LLC’s portfolio, making the stock its 13th biggest position.

  • [By Logan Wallace]

    SPDR KBW Bank (NYSEARCA:KBE) announced a quarterly dividend on Monday, June 18th, Wall Street Journal reports. Investors of record on Monday, June 18th will be paid a dividend of 0.1697 per share by the exchange traded fund on Wednesday, June 20th. This represents a $0.68 annualized dividend and a dividend yield of 1.38%. The ex-dividend date is Friday, June 15th. This is a boost from SPDR KBW Bank’s previous quarterly dividend of $0.16.

  • [By Jim Crumly]

    Retail had a good session, with the SPDR S&P Retail ETF (NYSEMKT:XRT) jumping 2.3%. Bank stocks also rose as long-term interest rates moved up; the SPDR S&P Bank ETF (NYSEMKT:KBE) added 1.3%. 

  • [By WWW.GURUFOCUS.COM]

    For the details of KELLOGG W K FOUNDATION TRUST’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=KELLOGG+W+K+FOUNDATION+TRUST

    These are the top 5 holdings of KELLOGG W K FOUNDATION TRUSTKellogg Co (K) – 67,606,838 shares, 98.23% of the total portfolio. Shares reduced by 0.48%SPDR Select Sector Fund – Energy Select Sector (XLE) – 769,255 shares, 1.19% of the total portfolio. SPDR S&P Bank (KBE) – 534,408 shares, 0.54% of the total portfolio. Shares reduced by 37.08%MuleSoft Inc (MULE) – 73,513 shares, 0.04% of the total portfolio. New PositioniShares Russell 1000 Value (IWD) – 0 shares, 0% of the total portfol

Leave a Reply

Your email address will not be published. Required fields are marked *